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An ongoing effort continues against the rising tide of antibiotic resistant bacteria, underscoring the urgent need to discover antibiotics with a novel mechanism of action. To this end, we have focused on the inhibition of the bacterial
enzyme N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE). Guided by docking with the computational suite Molecular Operating Environment (MOE) and lead molecules obtained through a HiTS (High Throughput Screening)
assay, several lead molecules and analogs were identified, synthesized, and optimized by our research group. These potential new inhibitors are tested in our recently described and updated biochemical DapE ninhydrin assay, with IC50
data obtained for inhibitors including cyclobutanone, tetrazole, pyrazole, sultam, and indoline sulfonamide analogs. To gain a greater understanding of the thermodynamic effects of these inhibitors on the binding of these synthesized
analogs with the DapE enzyme, we have employed a Thermal Shift Assay (TSA).

Methodology

Continued Work

Although the world currently faces a major battle against
the global COVID-19 pandemic, an ongoing fight continues
against an increase in antibiotic resistant bacteria,
underscoring the urgent need to discover antibiotics with a
new mechanism of action.1 We are investigating this
increase in mortality and morbidity to advance our fight
against antibiotic resistance. Our medicinal chemistry
research has revealed the possibility of a new class of
antibiotics, which targets a previously-unexplored
biochemical pathway, utilizing inhibition of
the enzymatic activity of N-succinyl-L,Ldiaminopimelic acid desuccinylase, or
DapE, as seen in Figure 1.2 This enzyme is
part of a crucial biosynthetic pathway that
produces the amino acid lysine and mDAP,
both essential to protein synthesis and
bacterial
peptidoglycan
cell
wall
construction, respectively. Therefore,
inhibition of DapE enzymatic activity is
very attractive because its inhibition
should be selectively lethal to bacteria,
while safe for mammals, as lysine is
received from our diet, and we do not Figure 1. DapE X-Ray
Crystal Structure (PDB
express the DapE enzyme.
5UEJ).2

Our ninhydrin assay3 is utilized to demonstrate inhibition of DapE representing potential antibiotic efficacy.
The assay consists of incubating the active DapE enzyme, a modified substrate, N6-methylsuccinyl
diaminopimelic acid (N6-Me-L,L-SDAP), HEPES buffer, DMSO solvent, and the inhibitor. The potential inhibitors
are tested at various concentrations at 30℃ for 10 minutes, followed by the quenching of the reaction and
deactivation of the enzyme by heating for 1 minute. Ninhydrin is added, reacting with the primary amine of
the now-cleaved product, as seen in Figure 2, converting the solution to Rhumann’s purple. The absorbance at
570 nm is measured in a spectrophotometer using a well-plate reader. The absorbance data obtained
represents the amount of substrate converted to product within the assay. These data are exported and
analyzed using Excel and PRISM to obtain IC50 values.3

Updates and improvements continue to be made to
streamline our assay to enable faster throughput and
more accurate results. A thermal cycler, an instrument
that automatically regulates the temperature of the
sample and the incubation time, is now employed in
obtaining C50 data. This enables the reduction of error,
increasing the accuracy of our results, which in turn aids
in every project in our group.

Objectives

Lead Molecules as DapE Inhibitors

Background

• Work in collaboration with graduate and undergraduate
students in our research group

In medicinal chemistry and drug discovery, IC50 refers to half the maximum inhibitory concentration. It is
utilized to compare the effect that potential drugs have on specific biological pathways or processes; therefore,
it is a common way to report inhibitory effects of small molecule drug candidates. Experimentally obtained IC50
data of novel compounds may be compared to that of previously identified DapE inhibitors, such as the thiolcontaining ACE inhibitor captopril, to determine their efficacy as potential new antibiotics.
Another means of improving upon our analogs and our overall understanding of the inhibition of the enzyme
is through the employment of a Thermal Shift Assay (TSA). This consists of analyzing the thermal denaturation
temperature of the DapE enzyme through the utilization of q-PCR to obtain fluorescence data. It involves of
the incubation of the active DapE enzyme, the modified substrate, HEPES buffer, DMSO solvent, the inhibitor,
and SYPRO Orange fluorogenic dye at increasing temperatures.

Figure 2. Hydrolysis of L,L-SDAP by DapE. L,L-SDAP (1a) and assay substrate N6-methyl-L,L-SDAP6 (1b) with formation of hydrolysis products
succinate (2) and L,L-diaminopimelic acid derivatives 3a and 3b, respectively.

Figure 3 contains the lead structure from each inhibitor series to demonstrate the wide variety of inhibitors being
tested in our critical assays. Some lead molecules are in their beginning stages of synthesis, while we have just
published advanced inhibitors based on the indolines 1 and 2.4

• Synthesize analogs of the original hits and obtain
inhibition data using the ninhydrin assay

• Use improved understanding to aid in future drug
synthesis for the optimization of new inhibitors
• Employ a Thermal Shift Assay (TSA) to further our
understanding of the thermodynamic effects of the
binding of the inhibitor analogs with the DapE enzyme

It is imperative to note our ongoing work to broaden
the scope of our research to combat growing antibiotic
resistance. We have set up the assay with the DapE
enzyme from an additional bacterial species, A.
baumannii (CSGID), to work toward confirming broad
spectrum antibiotic activity. We are working in
collaboration with CSGID (Center for Structural Genomics
of Infectious Diseases) at Northwestern as well as
Argonne National Laboratories to expand the validation of
DapE as a target for different types of bacterial infections.
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• Utilize the computational suite MOE and the lead
molecules obtained from HiTS to discover new inhibitor
series for DapE – tetrazoles, pyrazoles, sultams, indoline
sulfonamides,4 and cyclobutanones5

• Analyze the molecular interactions between DapE’s
structure and the inhibitors to gain greater
understanding of the enzyme dynamics involved in the
inhibition process

To further our understanding of the enzyme dynamics
taking place in the ninhydrin assay, we have been
conducting kinetic assays to obtain Ki data. With this
information, we will have an improved understanding of
the effects of the inhibitors on the enzyme.

Figure 3. Lead molecules as DapE inhibitors.

Results and Conclusions
Inhibition data for a series of indolines has recently published by our group.4 We have obtained preliminary
inhibition data for series 3 and 4 inhibitors, as well as for cyclobutanones, and this data will be published in
due course. Furthermore, after performing these reactions and obtaining DapE inhibition data, we will cocrystallize the drug candidates in collaboration with Northwestern CSGID and obtain high-resolution co-crystal
structures of the inhibitors with the DapE enzyme to elucidate the binding mode of the inhibitors as well as
the distinct enzyme conformations6 with the different compound moieties bound to the active sites. With this
information, we will be able to advance our understanding of the enzyme-drug interactions through an
improved knowledge of the structure activity relationship (SAR) between the different classes of inhibitors
with the enzyme, which will in turn enhance our effort toward the discovery of new antibiotics.
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